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Abstract:  COVID-19 is now a global pandemic, and an effective vaccine may be many months 
away.  Over 100 years ago, Spanish flu fatalities were attenuated when doctors began treating 
patients with blood plasma donated by recovered (or convalesced) survivors. Passive immunity 
transfer via administration of convalesced blood product (CBP) appears to represent a readily 
available and promising avenue for mitigating mortalities, expediting recovery time, and even 
prophylaxis against the SARS-CoV-2 virus.  Here, we review challenges to CBP efficacy, and 
present a graph theoretical model of transmission dynamics that identifies evolving “hubs” of 
COVID-19 cases. Importantly, this model suggests that CBP efficacy may rest on an efficient and 
distributed global sampling scheme as opposed to CBP pooled from local donors alone. 
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Introduction 
Transferring immunity from a recovered host to a newly infected patient is not novel. In 1890, 
serum extracted from animal hosts was used to treat children with diphtheria in one of the first 
noteworthy immunotherapy successes (1).   Prior to the age of antibiotics, antibody transfer 
from a recovered survivor to a newly infected recipient was widely used to treat human 
infectious diseases, and by the 1930s, over 80% of patients with type1 pneumonia admitted to 
a Boston hospital were treated with type-specific serum (2).  Although serotherapy was mostly 
applied during bacterial infections, viruses such as measles, mumps, varicella zoster, and 
poliomyelitis were treated with convalesced blood product (CBP). 
Recently, the SARS-Cov-2 virus has caused a global pandemic of alarming morbidity and 
mortality.  Common symptoms of COVID-19 resemble that of the severe acute respiratory 
syndrome (SARS) including fever, dry cough, difficulty breathing (dyspnoea), and fatigue (3). For 
approximately half of patients, the clinical course is uncomplicated with no abnormalities on 
chest radiographs (4)(5).  However, as the disease progresses, ground-glass opacities are 
reported on the majority of chest computerized-tomography images and ~6% of cases require 
mechanical ventilation (5). In many cases, the progression of the disease along with the 
radiographic findings appear to wax and wane (Figure 1A).  
Social distancing and public health measures ultimately put an end to the SARS outbreak of 
2002, which caused 774 fatalities (6) and an estimated $100 billion to the global economy (7).  
The SARS-Cov-2 pandemic, now orders of magnitude larger, will undoubtedly cause 
catastrophic economic burden, and the prolonged social distancing measures are expected to 
have a major impact on mental health (8). Unfortunately, there are currently no effective 
medications, vaccines or treatments for SARS-Cov-2, and there is an urgent need to identify 
target drugs and minimize the translational gap between preclinical testing and treatment (9). 
Ultimately, an effective vaccine may be many months away. 
In contrast, the historic practice of CBP administration represents a readily available 
therapeutic avenue for SARS-Cov-2.  Recent studies with other beta coronaviruses suggest that 
patients who received CBP had improved clinical outcomes for middle east respiratory 
syndrome (MERS) and SARS (10), though recent meta-analyses suggest mixed results (12)(13). 
Early reports suggest a clinical benefit for CBP in rescuing COVID-19 patients, albeit on small 
sample sizes (11).   
Overall, the long history of antibody therapeutics has provided insight into the some of the 
fundaments that subserve and are required for its efficacy.  Challenges to successful CBP 
therapy include unknown dose requirements, donor batch variability, mixed immunity transfer, 
serological and molecular diagnostic false positives, variable seroconversion rates, and timely 
distribution of strain-specific antibodies in the event the virus evolves.  Here, we review these 
key challenges and suggest a graph theoretic epidemiological model for predicting evolving 
needs and distributed strategies for CBP donor sampling.  
 
Convalescent Blood Therapeutics: Challenges with Preparation 
Convalescent blood products (CBP) can be used to achieve passive or artificially acquired 
immunity against infectious diseases, where neutralization is thought to be the primary 
mechanism of protection against viral infections (14). In the pre-antibiotic era, whole blood, 
plasma or serum were often derived from a single surviving host that had acquired active or 
humoral immunity to the infection.   
In recent years, immunoglobulin (Ig) for intravenous or intramuscular administration, high-titre 
human Ig, and polyclonal or monoclonal antibodies have become more common (15). 
Intravenous immunoglobulin (IVIG) is now typically prepared from the pooled plasma of 
thousands of donors containing primarily IgG, and only trace amounts of either IgM or IgA (16), 
the latter of which can induce anaphylactic reactions in patients with IgA deficiency. In recent 
decades, IVIG has become the gold standard treatment for an expanding number of 
autoimmune diseases, given its broad repertoire of neutralizing antibodies across a range of 
pathogens (17).   
Convalescent plasma therapy is generally considered safe (18). However, there are known 
adverse effects which should be considered in light of the patient’s specific risks for side effects 
in combination with disease mortality. Immediate and mild adverse reactions include general 
malaise or serum sickness.  Rare and delayed side effects are more severe including renal 
failure, thromboembolic events, neurological toxicity, and pulmonary complications (19). The 
risks of transmitting infections from donor to recipient (e.g., HIV) or from donor to a transfusion 
service personnel (e.g., COVID-19) also cannot be eliminated. Lastly, the half-life of IgG is 
approximately 3-4 weeks, thus treatments are required every few weeks (17). 
Unfortunately, there are significant challenges when producing IVIG for distribution.  Variability 
in the donor population, number of donors, and purification methods induces heterogeneity in 
the preparation (20). If plasma is taken from a (small) random sample of serologically positive 
donors, then there is a certain probability that the batch will be SARS-Cov-2 antibody poor.  
Methods for identifying donors rests on a combination of molecular and serological diagnostics.  
Unfortunately, both are unlikely to be positive simultaneously (Figure 1b).  
 
Timing (and Testing) is everything 
Ideally, both the viral strain and the immune response temporal profile would be well 
characterized for all CBP donors and recipients.  Acquiring this knowledge requires a minimum 
of two tests. First, a molecular diagnostic test would identify the viral strain, typically via a 
polymerase chain reaction (PCR) test operating on a nasopharyngeal or similar swab in 
combination with specifically designed primers or probes. Secondly, a serological test would 
identify the presence of SARS-Cov-2 specific antibodies, most commonly with the use an 
enzyme-linked immunosorbent assay (ELISA) serological test. 
Simultaneous administration of these two tests is unlikely to reveal both unknowns. PCR tests 
are typically positive during viral shedding, detected in the early stages of the disease.  Daily 
real-time PCR (RT-PCR) tests on COVID-19 patients revealed that these tests were positive for a 
median of 12 days (range 1-24) (4).   Antibodies are also typically produced in a unique 
temporal pattern across individuals in response to infection, as is the case with SARS-Cov-2.  
Preparing an ideal IVIG batch would require donation when there is a strong presence of IgG 
antibodies, and therefore delaying donations until IgM antibodies have subsided. In one patient 
reported, the IgM levels took at least 18 days to subside (3) (Figure 1B). 
It is also possible for the donor to test positive on the PCR test, yet negative on the serological 
test.  This might occur in the case of a PCR false positive, a serological false negative, or simply 
the case where the donor had a mild case and therefore produced very few antibodies which 
would subsequently be useful for CBP therapy.  In this case, the donor would be SARS-Cov-2 
antibody poor.   
Conversely, a potential donor may receive a false negative on a PCR test, which could be 
detrimental in the event that there is a scarcity of donors (Perez-Cameo 2020).  The majority of 
PCR primers are based on the Spike protein sequence as indexed with the original Wuhan strain 
(21).  Given that there are multiple co-circulating genotypes of SARS-Cov-2 (discussed below), it 
is possible that a primer may not anneal appropriately on an alternate strain.  
Timing of antibody receipt is also essential.  Studies during the SARS outbreak suggest that CBP 
infusion is most effective when the patient is both PCR positive and seronegative for the virus 
(10).  CBP therapy is generally most efficacious during the earliest stages of infection, and prior 
to production of a patients own immune response (2) (Figure 1C). The utility of CBP for COVID-
19 prophylaxis is unknown, but warrants further exploration. 
 
Evolutionary Transitions and Cross-Neutralization  
SARS-Cov-2 is a new founder beta coronavirus which consists of a single strand of positive sense 
RNA (22), and is the seventh coronavirus known to cross the species barrier into humans (23).  
Phylogenetic analyses suggest a zoonotic origin (animal etiology) due to its homology with 
SARS-like coronavirus found in bats (3), a natural reservoir for genetic variability of these 
viruses (24).   Considerable evidence from next generation and PCR sequencing now points to 
multiple co-circulating genotypes of SARS-Cov-2 (25);(26); (27).  In one study, at least 13 
variation sites were identified, with at least two in open reading frames having mutation rates 
of up to 30% (21).   
Antigenic drift typically results in mutations that have no discernible effect on clinical 
presentation.  For example, the D614G mutation due to antigenic drift has little effect on the 
rate of SARS-Cov-2 hospitalizations.  However, the G614 form quickly became the predominant 
strain around the globe forming its own “G-clade” haplotype (26). It is unknown if this 
increased prevalence was due to increased fitness or simply by random chance.  
Genetic reassortment amongst circulating strains is also an important factor in the evolutionary 
trajectory of coronaviruses (28); (24).  In order for reassortment to occur, two distinct parent 
strains must co-infect a host.  There is already evidence for genetic recombination in SARS-Cov-
2, with the emergence of the S9423P mutation identified across a variety of geographic 
locations in Belgium. The precise mechanism subtending the increased fitness of the G614 
mechanism is unknown.  However, one immunological hypothesis suggests that this form may 
mediate antibody escape, making a host susceptible to subsequent infections (26).   
Fortunately, viral progeny are often less pathogenic.  After all, a virus that rapidly kills its host is 
less likely infect another host successfully.  For example, the ancestral 1918 influenza A viral 
lineage still circulates today in a much more attenuated form (29).  Nonetheless, the ability to 
evade or alter immune response is an important factor of increased viral fitness.  
Importantly, it is unclear if immunity to one strand will effectively cross-neutralize an altered 
target.  Some evidence from the early SARS-Cov-2 strain suggested some cross-reactivity with 
horse serum (3).  However, the SARS-Cov virus shares ~79% homology with SARS-Cov-2, yet a 
number of tested monoclonal antibodies specific to receptor biding domains in SARS-Cov had 
low affinity for SARS-Cov-2, suggesting minimal antibody cross-neutralization (30).  
Predicting viral phenotypic properties from genetic sequences that have undergone antigenic 
drift and recombination remains very challenging.  Appreciating the prevalence of viral strains 
within geographic clusters and their associated networks may help model evolutionary 
trajectories and identify regions for increased viral surveillance and donor/sampling for CBP. 
The efficacy of CBP therapy may rely on identifying causal factors that lead to genetic shifts of 
immunological import - particularly given the short time window for which it must be 
administered. 
Small World Transmission Dynamics 
Complex systems, such as the epidemiology of SARS-Cov-2, can be described 
mathematically with the use of a graph. Complex network analysis, rooted in classical 
graph theory, has been used successfully to characterize statistical dependencies in 
large scale data ranging from social networks (31) to functional connections in the brain 
(32).  Importantly, structural or position data (nodes) can be explicitly defined along 
with their pairwise functional relationships (edges) on the same map, thus revealing 
topological correspondences between geographic structure and function (33).  
Here, we applied complex network analysis to the spread of COVID-19 throughout the 
US, whereby each state was considered as a node and the magnitude of case report 
temporal correlations are reflected in the links or edges (Figure 2).  This analysis is useful 
for classifying nodes into local cliques (modules), identifying hubs, as well as quantifying 
global properties of the network.  Interestingly, Washington State, where the initial case 
reports in the US occurred was never a highly connected or centralized hub, as revealed 
by the inner circle weights on connectograms (Figure 2c).  For additional results 
comparing relative and cumulative cases, please see Supplementary Results. New York 
was clearly a node with high degree (densely connected) that not only participates in 
the northeast modular structure, but also provides links with other cliques, and is 
therefore was important connector hub during the early spread of the disease.   In 
contrast, Maine has maintained a low degree of edges throughout the spread of the 
pandemic.   
Appreciating hubs can be useful for public health planning, predicting CBP need, and 
appropriate distribution of critical care supplies.  Geographically isolated regions with 
low degree and sparse connectivity (e.g., Maine) may also play an important role in 
shaping the genetic landscape.  Ecology, climate, and geographic distribution of viral 
strains help shape the tempo of viral evolution, and mutation hot spots are often 
surrounded by cold spots (34)(35).  The determinants of evolutionary rate variability for 
SARS-Cov-2 and the mosaic of reciprocal gene-host-environmental effects on fitness and 
the possibility of allopatric effects on strain diversity require further study.  
Geographically isolated communities can have strains that drift separately from more 
connected subpopulations.  To ensure a CBP pool that represents the broad repertoire 
of immunity, it may be advantageous to recruit blood donors from these regions as well. 
Small-worldness is a property of some networks whereby most nodes are not neighbors, 
but they can be reached in a small number of steps from all other nodes with a small 
average path length.  In this sense, small world networks represent a tradeoff between 
organized networks and those with random connectivity.  Interestingly, as the COVID-19 
pandemic spread throughout the US, the network became increasingly small world.  The 
implications of a small world COVID-19 epidemiological network topology on CBP 
therapy is that local donations alone are expected to fail in providing the diversity of 
immunity necessary for effective immunity transfer. 
Conclusions 
Convalescent blood products containing antibodies have been used for over a century in the 
setting of pandemics.  Although CBP usage declined after the introduction of antibiotics, it has 
continued to serve a crucial role in a number of outbreaks of viral etiology from West Nile virus 
to Ebola (14). During its therapeutic tenure, it has become clear that plasma from a single 
donor will not suffice.  Intravenously administered antibodies, pooled from thousands of 
donors, is now considered the gold standard treatment for a variety of autoimmune conditions.  
Furthermore, our graph theoretic results strongly suggest that not only will a single donor not 
suffice, but pooling blood from a single donor site or hospital is not expected to be sufficient 
either.   
At the onset of any pandemic, there are expected to be many more patients with active 
infections than those who have recovered. Randomized serological screening has provided 
evidence for the existence of asymptomatic infections, and immune response in 
paucisymtomatic individuals (18). Therefore, serological assays may be useful in identifying 
additional donors at the onset of a pandemic, in the event of a significant mutation of an 
existing virus, or in conditions of donor scarcity.  Although the duration of immunity to a 
particular strain of SARS-Cov-2 is unknown, there are examples of humans maintaining 
seroreactivity to the 1918 influenza nearly 90 years after exposure (36). Longitudinal studies of 
seroreactivity in convalesced COVID-19 patients are clearly needed to help inform CBP sampling 
strategies and appreciate the probability of reinfection.  
Serological assays alone will not provide the information necessary to understand how the 
clinical course of the disease and temporal profile of the immune response may differ across 
different viral strains and ecological factors. RNA viruses, in general, have a highly variable rate 
of evolution.  In one report, at least six different clades of SARS-Cov-2, distributed throughout 
the extant phylogenetic tree, were identified in different boroughs of New York (37). Major 
hubs for the pandemic are expected to have considerable genetic flow into and out of the 
region.  In this sense, sampling CBP from this densely connected hubs will likely provide 
immunity to a diversity of strains, but not to all strains.   
In our complex network analysis here, we identified cliques or modules as well as major 
connector hubs with high betweenness centrality.  This analysis also identified regions with very 
sparse connectivity with other regions in the US.  Our analysis was consistent with open source 
phylogenetic reports from NextStrain, suggesting that Washington state was never an early hub 
for COVID-19 spread throughout the US.  Given that the warmer seasonal weather failed to 
abate the disease, there has been more time for the perseveration of antigenic drift than for 
typical viruses.  It is possible that geographically isolated regions with reduced flow or 
connectivity may be more prone to diverging effects. These regions (e.g., Maine) should 
therefore be the target of sero-surveillance and molecular genetics testing programs until more 
is known about the environmental effect on natural selection and the trajectory of viral 
evolution.   
Thus far, a number of mathematical modeling tools have been developed to examine various 
aspects of SARS-Cov-2, including its phylogeography, and latent variable dynamics.  However, 
there is a critical need to integrate multimodal data across levels of abstraction within the 
context of predictive modeling (38), and to contextualize these findings for the purpose of 
effective CBP therapeutics.   
The small world network topology of SARS-Cov-2 spread suggests that enrolling donors via local 
programs alone is unlikely to provide a broad repertoire of immunity for effective treatment 
and potentially prophylaxis of COVID-19. With an increasingly itinerant society and small world 
epidemiological network properties, a coordinated global effort is crucial if the old CBP 
treatment is to be revived for novel therapeutic purposes.  
 
 
 
Figures: 
 
Figure 1: (a) A 67 year old female COVID-19 case.  From left to right: Baseline chest x-ray from 2014, 
initial presentation of COVID-19 4/13/20 showing bilateral areas of patchy airspace and along the lung 
periphery; 3 days later showing slight improvement of disease; CT scan 3 days later on 4/19/20 showing 
diffuse ground glass opacity corresponding to airspace disease on chest xray; the following day, chest x-
ray shows mild improvement; on 4/21/20 the disease worsened showing the overall waxing and waning 
of opacity in radiological findings.  (b) Serially collected polymerase chain reaction (PCR) data overlaid 
with serological assays collected serially; data reproduced from Zhou et al. 2020 & (39)Pan et al. 2020 (c) 
Flow diagrams illustrating convalescent blood product (CBP) treatment and donor pooling scenarios.  
(Upper left) the healthy individual is infected, and either acquires active immunity, a weak immune 
response, or the disease results in fatality.  (Middle left) The infected individual is treated with CBP in a 
timely manner and acquires passive immunity. (Lower Left) The individual is treated with CBP, yet the 
administration takes place after the individual’s immune response has initiated, and is therefore 
ineffective at conferring passive immunity.  (Upper Right) Pooling CBP from multiple donors is helpful, 
yet will only confer resistance to the diversity of strains present locally (Lower Right) Global pooling from 
multiple sites will yield passive immunity, and potentially preventative prophylaxis to a greater diversity 
of viral strains. 
Figure 2:  (a) Connectivity plots generated from the time course of cumulative (left) and relative (right) 
for cases (top) and deaths (bottom) (b) Connectogram plots of COVID-19 cases calculated for each month 
since the initial cases were reported.  These connectograms represent the correlations (connections) of 
the relative COVID case numbers within or across the large-scale communities in the United States 
according to their geographic position on the continent: the Northeast, Southeast, Southwest, West, and 
Midwest.  Areas on the outermost ring represent the 55 US states and territories (nodes), organized 
geographically into these six major communities. The outer circle circumscribes five inner circular 
heatmaps created to display the values of five centrality measures. Toward the center of the circle, the 
measures are degree centrality, participation coefficient, K-coreness centrality, eigenvector centrality, 
and PageRank. Values for each measure were mapped to colors, using a scheme that ranged from the 
minimum (white) to the maximum (fully saturated color) of the data set. Edges or links in the graph 
represent a temporal correlation that survived a 10% threshold between nodes; red and black connections 
represent the between-region and within-region COVID case relationships, respectively.  Highly connected 
subgroups or modules are clearly evident in the Northeast and Southeast.  Our analysis pipeline enables 
the reproduction of key figures, accessing the most up-to-date information (link to Github will be shared 
upon publication). 
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Supplementary methods  
Connectivity construction 
To perform complex network analysis, we first generated connectivity graphs comprised of nodes 
(US states and territories) connected by links (the Pearson’s correlation coefficient between each 
pair of nodes), using open source data updated regularly by the New York Times 
(https://github.com/nytimes/covid-19-data).  We constructed a symmetrical correlation matrix 
with a size of 55×55 for both COVID cases and deaths, relatively and cumulatively (Figure 2b). To 
examine the dynamic changes of COVID spread between the US states and territories, we formed 
the aforementioned correlation matrices on a monthly basis. To exclude the confounding effects 
of spurious links, we thresholded the correlation matrices to preserve a ratio of the strongest 
connections and remove weaker connections. This step is followed by binarizing the thresholded 
matrices to make the computational complexity and network representation more tractable.  
Computation of graph properties 
Using binary undirected matrices, we examined the topological properties of correlation network 
for each month (from February to August 2020) at both global and local levels. Global measures 
primarily reveal the functional segregation and integration of the brain network including the 
mean clustering coefficient, average shortest path length, and small-worldness (31, 32, 33). Local 
properties are calculated for each individual node (US states and territories) separately, reflecting 
the nodal centrality and density of hubs (either connector or provincial) in the network. In this 
study, we calculated the most common centrality metrics such as degree, participation 
coefficient, K-coreness centrality, eigenvector centrality, and PageRank (33).  
 
Global properties: Supplementary figure 1 depicts the variations of computed global measures 
for COVID case networks across the time (monthly). The clustering coefficient quantifies the 
extent to which the neighbors of a given node are interconnected. A a higher mean clustering 
coefficient value indicates the prevalence of strongly interconnected communities. Characteristic 
path length reflects the global viral transmission of the network by averaging the shortest path 
length across all pairs. Small-world networks are neither random nor regular, and consisting of a 
large number of short-range connections alongside a few long-range shortcuts. Mathematically, 
small-world networks have a high clustering coefficient and short average path length, which 
makes them superior to other networks in terms of local segregation and global integration (31, 
33). A small-worldness higher than 1 reflects the efficiency of the connectivity network (33), 
indicating a health hazard in COVID spread, for example.  Interestingly, the small-worldness of 
covid transmission appeared to peak in May, coinciding with the reopening of many states, 
reduced social distancing, and return to domestic travel. 
 
Supplementary Figure 1. Changes of global properties in the correlation network of COVID cases across the time. 
 
Local properties: The monthly connectivity profiles within/between the US regions are visualized 
in Figure 3 (sparsity level of 0.1) using Circos software (Krzywinski et al., 2009). Areas on the 
outermost circle represent the 55 US states and territories in six major communities. This outer 
circle circumscribes five inner circular heatmaps created to display the values of five centrality 
measures. Toward the center of the circle, the measures are degree centrality, participation 
coefficient, K-coreness centrality, eigenvector centrality, and PageRank. Values for each measure 
were mapped to colors, using a scheme that ranged from the minimum to the maximum of the 
data set. The red and black curves indicate the correlations (connections) of the relative COVID 
cases between and within communities, respectively (see Figure 2c). 
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